June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Downregulation of the SIRT1 and Liver X Receptor α/β signaling axis promotes diabetic retinopathy pathogenesis
Author Affiliations & Notes
  • Sandra Hammer
    Physiology, Michigan State University, East Lansing, Michigan, United States
  • Todd Lydic
    Physiology, Michigan State University, East Lansing, Michigan, United States
  • Qi Wang
    Physiology, Michigan State University, East Lansing, Michigan, United States
  • Sugata Hazra
    The University of Utah, Salt Lake City, Utah, United States
  • Goldis Malek
    Duke Univeristy, Durham, North Carolina, United States
  • Michael E Boulton
    Indiana University , Indianapolis, Indiana, United States
  • Maria B Grant
    Indiana University , Indianapolis, Indiana, United States
  • Julia V Busik
    Physiology, Michigan State University, East Lansing, Michigan, United States
  • Footnotes
    Commercial Relationships   Sandra Hammer, None; Todd Lydic, None; Qi Wang, None; Sugata Hazra, None; Goldis Malek, None; Michael Boulton, None; Maria Grant, None; Julia Busik, None
  • Footnotes
    Support  NH Grant EY025383
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4248. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Sandra Hammer, Todd Lydic, Qi Wang, Sugata Hazra, Goldis Malek, Michael E Boulton, Maria B Grant, Julia V Busik; Downregulation of the SIRT1 and Liver X Receptor α/β signaling axis promotes diabetic retinopathy pathogenesis. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4248.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Clinical trials have demonstrated a strong association between dyslipidemia and the progression of diabetic retinopathy (DR). Activation of LXRα/β prevents diabetes-induced retinal vascular damage. Moreover, SIRT1-mediated LXR activation has been shown to be beneficial in non-retinal systems, but the involvement of this signaling axis in DR remains unknown. The goal of this project was to investigate the role that the SIRT1-LXR signaling cascade plays in the progression of DR.

Methods : Bovine retinal endothelial cells (BRECs) were isolated and validated according to a previously published protocol. Human retinal endothelial cells (HRECs) were isolated from control or diabetic patients. BRECs and HRECs were treated with TNFα (10ng) for 24hrs. DMHCA (1ug) was used as a LXR activator. LXRα/β, SIRT1, CYP46A1, -27A1, -11A1, ABCA1 and -G1 were analyzed by qRT-PCR. Oxysterols and cholesterol esters were measured by high resolution/accurate mass LC-MS and direct infusion MS, respectively, on an Orbitrap Velos mass spectrometer. db/db diabetic mice were used to model diabetic retinopathy in vivo.

Results : HRECs isolated from diabetic donors had significantly lower expression levels of LXRα/β and SIRT1 when compared to non-diabetic donors (n=6; p<0.01). Additionally, LXRα was significantly decreased in BRECs and control HRECs treated with TNFα (10ng/ml) (n=9, n=3; p<0.01, respectively). Cholesterol metabolizing enzymes, CYP46A1 and -11A1 were significantly increased after TNFα treatment (n=9; p<0.05) in BREC while CYP46A1, -27A1 and -11A1 were downregulated in control HRECs after TNFα treatment (n=3; p<0.01). LXR activation (DMHCA) prevented TNFα-induced ABCA1 and -G1 downregulation (n=9; p<0.05). Oxysterol levels were decreased (n=9; p<0.05) and total retinal cholesterol ester abundance was increased in diabetic animals compared to control animals. Lastly, retinal levels of SIRT1 and LXRα/β were downregulated in diabetic mice after 8 weeks of diabetes and LXR activation prevented development of acellular capillaries in db/db mice (n=6; p<0.05).

Conclusions : This study demonstrates the detrimental effect diabetes has on LXR and SIRT1 retinal levels. Activation of LXR prevents DR-induced pathology in diabetic animals. Hence, these studies suggest that retinal-specific activation of LXR has the potential to be a novel therapeutic target in the treatment of DR.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×